Yujiro Hata - Mar 6, 2024 Form 4 Insider Report for ENANTA PHARMACEUTICALS INC (ENTA)

Role
Director
Signature
/s/ Paul J. Mellett as attorney-in-fact
Stock symbol
ENTA
Transactions as of
Mar 6, 2024
Transactions value $
$0
Form type
4
Date filed
3/8/2024, 05:19 PM
Previous filing
Mar 4, 2024
Next filing
May 16, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ENTA Stock Option (right to buy) Award $0 +15.7K $0.00 15.7K Mar 6, 2024 Common Stock 15.7K $15.66 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Such option will become exercisable monthly in substantially equal installments over one year, beginning from the date of grant (March 6, 2024), with the final monthly installment vesting on the nearest trading day on the Nasdaq Global Select Market preceding the 2025 annual meeting of stockholders.